Teneligliptin 20mg + Metformin 500mg SR Tablet in PCD pharma franchise in Hyderabad

Teneligliptin 20mg + Metformin 500mg SR Tablet in pharmaceutical manufacturing company in Mumbai

Teneligliptin 20mg + Metformin 500mg SR Tablet in antidiabetic pharma franchise in Pune

Teneligliptin 20mg + Metformin 500mg SR Tablet in pharma suppliers in Delhi

Teneligliptin 20mg + Metformin 500mg SR Tablet in pharma export companies in Kolkata
Teneligliptin 20mg + Metformin 500mg SR Tablet in pharma franchise opportunities in Bengaluru

Tenelit M Tablet

Composition : Tenlegliptin HCL I.P. 20mg + Metformin HCL I.P. 500mg (S.R.) Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹139/-

Please Contact For Best Price

Tenelit M Tablet is a bi-layered formulation combining Teneligliptin 20mg, a potent DPP-4 inhibitor, with Metformin 500mg (sustained release), a well-established biguanide antidiabetic agent. This combination provides a complementary dual action to effectively control blood glucose levels in patients with type 2 diabetes mellitus. Teneligliptin enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner, while Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release form of Metformin ensures a gradual and steady release, minimizing gastrointestinal side effects and improving patient compliance. Tenelit M supports better glycemic control without significant risk of hypoglycemia or weight gain, making it an effective option in comprehensive diabetes management alongside diet and exercise.

Read More

About the Product

Tenelit M Tablet is a bi-layered formulation combining Teneligliptin 20mg, a potent DPP-4 inhibitor, with Metformin 500mg (sustained release), a well-established biguanide antidiabetic agent. This combination provides a complementary dual action to effectively control blood glucose levels in patients with type 2 diabetes mellitus. Teneligliptin enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner, while Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release form of Metformin ensures a gradual and steady release, minimizing gastrointestinal side effects and improving patient compliance. Tenelit M supports better glycemic control without significant risk of hypoglycemia or weight gain, making it an effective option in comprehensive diabetes management alongside diet and exercise.

Common side effects include mild gastrointestinal discomfort such as nausea, diarrhea, and abdominal pain due to Metformin. Teneligliptin is generally well tolerated but may cause headache or nasopharyngitis. Hypoglycemia risk is low but may increase when combined with other glucose-lowering agents.

Indicated for the treatment of type 2 diabetes mellitus, particularly when diet and exercise alone do not provide adequate glycemic control. It can be used as monotherapy or in combination with other antidiabetic agents.

Not recommended for patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment. Regular monitoring of renal function and blood glucose levels is advised. Use caution in patients with hepatic impairment. Consult a physician before use during pregnancy or lactation.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of the reach of children.

Get in Touch